Company Performance Metrics
As the cost of next-generation sequencing technology continues to drop, this has created an environment where molecular tumor profiling is more accessible than ever before. Despite these advances, there remains a challenge: the ability to analyze and accurately interpret the overwhelming amount of genomic and therapeutic data now available via next
generation sequencing.
Lifecode is dedicated to translating and presenting this new information in a meaningful way for patients, payers and providers. Towards this end Lifecode has built an exceptional team of talented individuals with expertise in data science, software engineering, computational biology, bio-informatics, machine learning, curation science, molecular biology, and pathology.
With funding from both Sequoia Capital and The Mayo Clinic, Lifecode has the DNA of both a software company and a world-class clinical lab.
Their flagship assay, the Lifecode Pan Cancer Somatic Panel is currently being offered on a limited basis to a select number of physicians in the United States.
Lifecode is seeking extremely talented and hardworking individuals who share their passion for genomically driven, personalized cancer care.
